Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5690194 | 1.00 | ESR2 (0.54) | ESR2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL5690198 | 1.00 | ESR2 (0.54) | ESR2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL8335098 | 1.00 | ESR2 (0.54) | ESR2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL7288906 | 0.90 | ESR2 (0.60) | ESR2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL15369698 | 0.86 | ESR2 (0.48) | ESR2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL11042278 | 0.85 | ESR2 (0.52) | ESR2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL11042279 | 0.85 | ESR2 (0.52) | ESR2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL11045272 | 0.83 | ESR2 (0.46) | ESR2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL28302940 | 0.79 | ESR2 (0.60) | ESR2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL5690699 | 0.79 | ESR2 (0.48) | ESR2KDM4EALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122678-B2 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | WARNER-LAMBERT COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1032555-B1 | CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF USEFUL AS PHARMACEUTICAL AGENTS | WARNER LAMBERT CO (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1157000-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | WARNER LAMBERT CO (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1572184-A1 | GABAPENTIN ANALOGUES FOR FIBROMYALGIA AND OTHER RELATED DISORDERS | WARNER-LAMBERT COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6921835-B2 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | WARNER LAMBERT COMPANY (US) | 2005-07-26 | — | — | US | disclosed |
| US-20050159487-A1 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | BRYANS JUSTIN S (GB) | 2005-07-21 | — | — | US | disclosed |
| US-20040180959-A1 | Gabapentin analogues for fibromy algia and concomitant disorders | DOOLEY DAVID JAMES (US) | 2004-09-16 | — | — | US | disclosed |
| WO-2004054564-A1 | GABAPENTIN ANALOGUES FOR FIBROMYALGIA AND OTHER RELATED DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20030220397-A1 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-11-27 | — | — | US | disclosed |
| US-6635673-B1 | 1-Aminomethyl-3,4-dimethyl-cyclopentyl acetic acid; epilepsy; neurodegenerative, neuropathological and gastrointestinal disorders; depression, anxiety, panic, pain | WARNER-LAMBERT COMPANY | 2003-10-21 | — | — | US | disclosed |
| EP-1157000-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | WARNER-LAMBERT COMPANY (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2001042191-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | WARNER-LAMBERT COMPANY (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-1032555-A1 | CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999021824-A1 | CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220397-A1 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | APC, VIP, NPSR1 | ESR2 3468/4885KDM4E 4338/4885ALDH1A1 3481/4885 |
| US-20040180959-A1 | Gabapentin analogues for fibromy algia and concomitant disorders | PKD2, CACNA1S, CACNA1B | ESR2 3217/4885KDM4E 3915/4885ALDH1A1 1165/4885 |
| US-20050159487-A1 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | APC, VIP, NPSR1 | ESR2 3468/4885KDM4E 4338/4885ALDH1A1 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.